Austar Lifesciences Ltd. (HK:6118) has released an update.
Austar Lifesciences Limited has released its interim financial results for the first half of 2024, showcasing a return to profitability with a profit before income tax of RMB 9,186,000, compared to a loss in the same period in 2023. The company reported a gross profit of RMB 145,417,000 and a modest increase in gross profit margin to 20.75%, despite a decrease in revenue from the previous year. The results indicate a positive shift in the company’s financial performance, with basic and diluted earnings per share both at RMB 0.01.
For further insights into HK:6118 stock, check out TipRanks’ Stock Analysis page.
